Analysis of Biopharmaceutical Innovation Investment in China and Its Policy Causes——On the Basis of the Status Quo of Innovation Investment in United States, Europe and China by Empirical Evaluation

DING Jin-xi,JI Na,LI Xiao-ting,SUN Xiao-dong
DOI: https://doi.org/10.3969/j.issn.1004-115x.2012.04.003
2012-01-01
Abstract:During these years,the RD of China's innovative drug has attracted more and more attention.Although the RD investments are increasing year by year,obvious gap is still existing when compared with foreign.This paper used quantitative comparison to compare the input and the construction of RD investments of the US,EU and China innovative drugs by empirical evaluation,aiming to profoundly research the present situation and policy causes of the RD investments of Chinese biopharmaceutical industry.Furthermore,we would like to make some suggestions to promote the innovative institution of Chinese biopharmaceutical industry.
What problem does this paper attempt to address?